No data to show
XHKG
2171
Market cap1.79bUSD
Jun 16, Last price
24.45HKD
1D
4.94%
1Q
85.23%
IPO
-16.70%
Name
CARsgen Therapeutics Holdings Ltd
Chart & Performance
P/E
—
P/S
326.53
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.52%
Rev. gr., 5y
%
Revenues
39m
Net income
-798m
L+6.73%
CFO
-410m
L-9.95%
Profile
CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product candidate that is in pivotal Phase II trial for the treatment of relapsed/refractory multiple myeloma in China; CT041, an autologous CAR-T product candidate that is in Phase Ib/II clinical trial for advanced gastric/gastroesophageal junction cancer and pancreatic cancer in China, as well as in Phase Ib clinical trial for advanced gastric or pancreatic cancer in the United States; and CT011, an autologous CAR-T product candidate that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, an autologous CAR-T products candidate that is in Phase I/II clinical trial for the treatment of B cell Non-Hodgkin's lymphoma in China; AB011, a humanized monoclonal antibody product candidate that is in Phase I clinical trial for the treatment of CLDN18.2 positive solid tumors in China; and CT017, an autologous Glypican-3-targeted CAR-T product candidate for the treatment of hepatocellular carcinoma, as well as other product candidates for the treatment of solid tumors. The company was founded in 2014 and is headquartered in Shanghai, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 39,425 | |||||
Cost of revenue | 646,960 | 794,971 | 727,123 | |||
Unusual Expense (Income) | ||||||
NOPBT | (607,535) | (794,971) | (727,123) | |||
NOPBT Margin | ||||||
Operating Taxes | 346 | 407 | 1,295 | |||
Tax Rate | ||||||
NOPAT | (607,881) | (795,378) | (728,418) | |||
Net income | (798,132) 6.73% | (747,794) -16.19% | (892,247) -81.19% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 6,610 | 10,505 | ||||
BB yield | -0.18% | -0.13% | ||||
| Debt | ||||||
Debt current | 33,728 | 14,752 | 21,984 | |||
Long-term debt | 209,979 | 153,166 | 209,533 | |||
Deferred revenue | 188,829 | 21,180 | ||||
Other long-term liabilities | 229,626 | (3) | ||||
Net debt | (1,235,351) | (1,682,962) | (2,036,519) | |||
| Cash flow | ||||||
Cash from operating activities | (409,690) | (454,935) | (643,048) | |||
CAPEX | (8,835) | (138,614) | ||||
Cash from investing activities | 12,522 | 39,251 | 2,386,990 | |||
Cash from financing activities | 18,457 | (22,142) | (236,514) | |||
FCF | (370,440) | (719,905) | (780,515) | |||
| Balance | ||||||
Cash | 1,479,058 | 1,850,880 | 2,268,036 | |||
Long term investments | ||||||
Excess cash | 1,477,087 | 1,850,880 | 2,268,036 | |||
Stockholders' equity | 1,056,707 | (8,189,828) | (7,441,549) | |||
Invested Capital | 396,048 | 10,265,577 | 10,049,911 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 552,875 | 556,125 | 551,626 | |||
Price | 9.21 41.69% | 6.50 -56.61% | 14.98 -44.21% | |||
Market cap | 5,091,979 40.86% | 3,614,812 -56.25% | 8,263,357 -20.44% | |||
EV | 3,856,628 | 1,931,850 | 6,226,838 | |||
EBITDA | (527,980) | (707,576) | (645,590) | |||
EV/EBITDA | ||||||
Interest | 15,521 | |||||
Interest/NOPBT | ||||||